Notice2022-08302
Yvelice Villaman-Bencosme: Final Debarment Order
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 19, 2022
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA or Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Yvelice Villaman-Bencosme from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Yvelice Villaman-Bencosme was convicted of a felony under Federal law for conduct relating to the development or approval, including the process of development or approval, of a drug product under the FD&C Act. Ms. Villaman-Bencosme was given notice of the proposed permanent debarment and was given an opportunity to request a hearing to show why she should not be debarred. As of December 13, 2021 (30 days after receipt of the notice), Ms. Villaman-Bencosme had not responded. Ms. Villaman- Bencosme's failure to respond and request a hearing constitutes a waiver of her right to a hearing concerning this action.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 75 (Tuesday, April 19, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 75 (Tuesday, April 19, 2022)]
[Notices]
[Pages 23184-23185]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-08302]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2021-N-0317]
Yvelice Villaman-Bencosme: Final Debarment Order
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is issuing an
order under the Federal Food, Drug, and Cosmetic Act (FD&C Act)
permanently debarring Yvelice Villaman-Bencosme from providing services
in any capacity to a person that has an approved or pending drug
product application. FDA bases this order on a finding that Yvelice
Villaman-Bencosme was convicted of a felony under Federal law for
conduct relating to the development or approval, including the process
of development or approval, of a drug product under the FD&C Act. Ms.
Villaman-Bencosme was given notice of the proposed permanent debarment
and was given an opportunity to request a hearing to show why she
should not be debarred. As of December 13, 2021 (30 days after receipt
of the notice), Ms. Villaman-Bencosme had not responded. Ms. Villaman-
Bencosme's failure to respond and request a hearing constitutes a
waiver of her right to a hearing concerning this action.
DATES: This order is applicable April 19, 2022.
ADDRESSES: Submit applications for termination of debarment to the
Dockets Management Staff, Food and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, or at <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
FOR FURTHER INFORMATION CONTACT: Jaime Espinosa, Division of
Enforcement (ELEM-4029), Office of Strategic Planning and Operational
Policy, Office of Regulatory Affairs, Food and Drug Administration,
12420 Parklawn Dr., Rockville, MD 20857, 240-402-8743,
<a href="/cdn-cgi/l/email-protection#caaeafa8abb8a7afa4beb98aacaeabe4a2a2b9e4ada5bc"><span class="__cf_email__" data-cfemail="bbdfded9dac9d6ded5cfc8fbdddfda95d3d3c895dcd4cd">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
I. Background
Section 306(a)(2)(A) of the FD&C Act (21 U.S.C. 335a(a)(2)(A))
requires debarment of an individual from providing services in any
capacity to a person that has an approved or pending drug product
application if FDA finds that the individual has been convicted of a
felony under Federal law for conduct relating to the development or
approval, including the process of development or approval, of any drug
product under the FD&C Act. On March 19, 2021, Ms. Villaman-Bencosme
was convicted as defined in section 306(l)(1) of the FD&C Act when
judgment was entered against her in the U.S. District Court for the
Southern District of Florida-Miami Division, after her plea of guilty,
to one count of Conspiracy to Commit Wire Fraud in violation of 18
U.S.C. 1349.
The factual basis for this conviction is as follows: Ms. Villaman-
Bencosme was a licensed medical doctor who served as a clinical
investigator at Unlimited Medical Research, LLC from about September
2013 through June 2016. Ms. Villaman-Bencosme conspired with others to
unlawfully enrich herself by making materially false representations
about clinical trials; fabricating data and the participation of
subjects in those clinical trials; concealing from FDA, sponsors, and
contract research organizations the fact that the data and
participation of subjects had been
[[Page 23185]]
fabricated; and inducing sponsors and contract research organizations
to pay money for Ms. Villaman-Bencosme and her co-conspirators' own
benefit. On or about October 25, 2013, Ms. Villaman-Bencosme entered
into a contract with a Contract Research Organization retained by a
drug manufacturer (Sponsor) to serve as a clinical investigator for a
clinical trial initiated by the Sponsor. The study was for an
investigational drug intended to treat pediatric asthma in children
between the ages of 4 and 11 years. As the clinical investigator Ms.
Villaman-Bencosme was responsible for all aspects of the study to
include ensuring that subjects provided informed consent and understood
the risks of participating in the study, reporting adverse events to
the Sponsor, and maintaining honest and accurate records known as
``case histories.'' Instead, Ms. Villaman-Bencosme used personal
identification information from pediatric patient medical records
maintained at her private medical practice to falsify case histories.
This included a number of false details. Ms. Villaman-Bencosme made it
appear that: The study subjects satisfied the eligibility criteria to
participate in the study; the subjects received a physical examination
from her; the patients received the study drug at the study site; the
patients returned the study drug to the study site; and the patients
received payment for visits to the study site.
As a result of this conviction, FDA sent Ms. Villaman-Bencosme by
certified mail on November 3, 2021, a notice proposing to permanently
debar her from providing services in any capacity to a person that has
an approved or pending drug product application. The proposal was based
on a finding, under section 306(a)(2)(A) of the FD&C Act, that Ms.
Villaman-Bencosme was convicted of a felony under Federal law for
conduct relating to the development or approval, including the process
of development or approval, of any drug product under the FD&C Act. The
proposal also offered Ms. Villaman-Bencosme an opportunity to request a
hearing, providing her 30 days from the date of receipt of the letter
in which to file the request, and advised her that failure to request a
hearing constituted an election not to use the opportunity for a
hearing and a waiver of any contentions concerning this action. Ms.
Villaman-Bencosme received the proposal on November 13, 2021. She did
not request a hearing within the timeframe prescribed by regulation and
has, therefore, waived her opportunity for a hearing and any
contentions concerning her debarment (21 CFR part 12).
II. Findings and Order
Therefore, the Assistant Commissioner, Office of Human and Animal
Food Operations, under section 306(a)(2)(A) of the FD&C Act, under
authority delegated to the Assistant Commissioner, finds that Ms.
Villaman-Bencosme has been convicted of a felony under Federal law for
conduct relating to the development or approval, including the process
of development or approval, of any drug product under the FD&C Act.
As a result of the foregoing finding, Ms. Villaman-Bencosme, is
permanently debarred from providing services in any capacity to a
person with an approved or pending drug product application, effective
(see DATES) (see sections 306(a)(2)(A) and 306(c)(2)(A)(ii) of the FD&C
Act). Any person with an approved or pending drug product application
who knowingly employs or retains as a consultant or contractor, or
otherwise uses the services of Ms. Villaman-Bencosme, in any capacity
during her debarment, will be subject to civil money penalties (section
307(a)(6) of the FD&C Act (21 U.S.C. 335b(a)(6))). If Ms. Villaman-
Bencosme provides services in any capacity to a person with an approved
or pending drug product application during her period of debarment, she
will be subject to civil money penalties (section 307(a)(7) of the FD&C
Act). In addition, FDA will not accept or review any abbreviated new
drug application from Ms. Villaman-Bencosme during her period of
debarment, other than in connection with an audit under section 306 of
the FD&C Act (section 306(c)(1)(B) of the FD&C Act). Note that, for
purposes of sections 306 and 307 of the FD&C Act, a ``drug product'' is
defined as a ``drug subject to regulation under section 505, 512, or
802 of this Act [(21 U.S.C. 355, 360b, 382)] or under section 351 of
the Public Health Service Act [(42 U.S.C. 262)]'' (section 201(dd) of
the FD&C Act (21 U.S.C. 321(dd)).
Any application by Ms. Villaman-Bencosme for special termination of
debarment under section 306(d)(4) of the FD&C Act should be identified
with Docket No. FDA-2021-N-0317 and sent to the Dockets Management
Staff (see ADDRESSES). The public availability of information in these
submissions is governed by 21 CFR 10.20.
Publicly available submissions will be placed in the docket and
will be viewable at <a href="https://www.regulations.gov">https://www.regulations.gov</a> or at the Dockets
Management Staff (see ADDRESSES) between 9 a.m. and 4 p.m., Monday
through Friday, 240-402-7500.
Dated: April 12, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-08302 Filed 4-18-22; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on April 19, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.